FindTrial
Sign In

Blood pressure control using Carvedilol drug in dialysis dependent patients

Blood pressure control with Carvedilol in dialysis dependent End Stage Renal Disease patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012700
Enrollment
30
Registered
2018-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- End Stage Renal Disease Patients on hemodialysis

Interventions

Intervention1: carvedilol: antihypertensive agent Control Intervention1: not applicable: not applicable

Sponsors

none
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: β-Blocker-Metoprolol, treated hypertensive ESRD patients on dialysis(hemodialysis) with uncontrolled hypertension would be recruited at the Department of Nephrology. Uncontrolled hypertension would be defined as seated office systolic and/or diastolic BP >=140/90 mm Hg calculated from the average of the second and the third readings of 3 consecutive measurements.

Exclusion criteria

Exclusion criteria: 1) Patients with severe hypertension (BP >=180/110 mm Hg), atrial fibrillation, or contraindications for β-blocker use. 2) Patients with chronic liver disease.

Design outcomes

Primary

MeasureTime frame
the variation in blood pressure post change of metoprolol to carvedilol in dialysis patients.Timepoint: six months—

Secondary

MeasureTime frame
noneTimepoint: none—

Countries

India

Contacts

Public ContactABHILASH CHANDRA

Dr.RMLIMS

acn393@gmail.com9935893823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026